Kintara Therapeutics Inc at Reed Smith Disruptive Growth Conference Transcript
-- clinical-stage biopharmaceutical company focused on development and commercialization of new cancer therapies, ticker KTRA. Here to speak upon it is Robert Hoffman, President and CEO.
Thank you. Appreciate the invite for being here and looking forward to telling you a little bit about why I joined Kintara Therapeutics last year, actually, as CEO.
Before I begin, I'd like to point out will be making numerous forward-looking presentations during this presentation. Actual results may differ, so please refer to the risk factors on file with the SEC.
And again, I'll tell you a little bit about me because lately I've been getting the question, why did you take this job? So, a little bit about me. I joined biotech back in 1997 as the first non-founding employee at Arena Pharmaceuticals. I was there about 17 years, the last 10 years as CFO. I took the company public in 2000, did many transactions -- Eli Lilly, J&J, Merck, different
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |